<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137990">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02073981</url>
  </required_header>
  <id_info>
    <org_study_id>J-FIRST</org_study_id>
    <nct_id>NCT02073981</nct_id>
  </id_info>
  <brief_title>Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients</brief_title>
  <acronym>J-FIRST</acronym>
  <official_title>Japan-First-in Large Scale Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Company, Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Company, Limited</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Ministry of Education, Culture, Sports, Science and Technology</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is implemented to identify factors having an impact on improvement or
      exacerbation of non-motor symptoms, to provide information contributing to development of
      medical care in this field and improvement of patients' QOL, and to clarify the association
      between the use of istradefylline and non-motor symptoms or QOL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changing of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>MDS-UPDRS score will be collected from all registrant at each visit and on the last day of survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changing of Parkinson's Disease Questionaire-8 (PDQ-8) score.</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PDQ-8 score will be collected from all registrant at each visit and on the last day of survey.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson Disease</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have wearing off under treatment with levodopa-containing drugs
             administered at least three times daily

          -  Patients who have at least one non-motor symptom as a complication

          -  Patients at least 20 years of age at the time of consent

          -  Patients who have given written consent

          -  Patients who are receiving outpatient care

        Exclusion Criteria:

          -  Patients with dementia or a score of 23 or less on the Mini-Mental State Examination
             (MMSE)

          -  Patients, in the opinion of the investigator or subinvestigator, having conditions
             impairing the proper assessment of the MDS-UPDRS or PDQ-8 (e.g., patients who are
             receiving treatment for malignant tumor)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Hakko Kirin Company, Limited</last_name>
    <email>clinical.info@kyowa-kirin.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Hakko Kirin Company, Limited</last_name>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
